Jubilant Pharmaceutical INC
Balance Sheet as at 31 March 2026
(All amounts in CAD, unless otherwise stated)

	Notes	As at 31 March 2026
ASSETS		
Non-current assets		
Deferred tax assets (net)		10,874
Total non-current assets		**10,874**
Current assets		
Financial assets		
i. Cash and cash equivalents	3	29,965
Total current assets		**29,965**
Total assets		**40,839**
EQUITY AND LIABILITIES		
Equity		
Equity share capital	4	30,000
Other equity		(30,159)
Total equity		**(159)**
Liabilities		
Current liabilities		
Financial liabilities		
i. Trade payables	5	40,998
Total current liabilities		**40,998**
Total liabilities		**40,998**
Total equity and liabilities		**40,839**

For Jubilant Pharmaceutical INC

Krishna Khaitan
(Director)
Date: 19 May 2026

Jubilant Pharmaceutical INC
Statement of Profit and Loss for the year ended 31 March 2026
(All amounts in CAD, unless otherwise stated)

	Notes	For the year ended 31 March 2026
Revenue from operations		-
Total income		**-**
Expenses		
Other expenses	6	41,033
Total expenses		**41,033**
Loss before exceptional items and tax		**(41,033)**
Exceptional items		-
Loss before tax		**(41,033)**
Tax expense		
- Current tax		-
- Deferred tax (credit)		(10,874)
Total tax expense		**(10,874)**
Loss for the year		**(30,159)**
Other comprehensive loss for the year, net of tax		**-**
Total comprehensive loss for the year		**(30,159)**

Jubilant Pharmaceutical INC
Statement of Cash Flows for the year ended 31 March 2026
(All amounts in CAD, unless otherwise stated)

	As at 31 March 2026
A. Cash flow from operating activities	
Net profit before tax	(41,033)
Operating cash flow before working capital changes	**(41,033)**
Increase in trade payables, other financial liabilities, other liabilities and provisions	40,998
Cash (Used in) operations	**(35)**
Income tax paid (net of refund)	-
Net cash (used in) operating activities	**(35)**
B. Cash flow from financing activities	
Proceeds from issue of share capital	30,000
Net cash generated from financing activities	**30,000**
Net increase in cash and cash equivalents (A+B)	**29,965**
Cash and cash equivalents at the beginning of year	-
Cash and cash equivalents at the end of the year	**29,965**

Jubilant Pharmaceutical INC
Statement of Changes in Equity for the year ended 31 March 2026
(All amounts in CAD, unless otherwise stated)

A. Equity share capital	**Amount**
Changes in equity share capital during the year	30,000
Balance as at 31 March 2026	**30,000**

B. Other equity

	Reserves and surplus	**Total**
	Retained earnings	
Profit for the year	**(30,159)**	**(30,159)**
Total comprehensive income for the year	**(30,159)**	**(30,159)**
Balance as at 31 March 2026	**(30,159)**	**(30,159)**

Note 1: Corporate information

Jubilant Pharmaceutical INC ("the Company") is a for-profit proprietary Company, incorporated on 17th June, 2025 and domiciled in Canada. The Company is a wholly owned subsidiary of Jubilant Generics Limited ("the holding company") whose ultimate parent company is Jubilant Pharmova Limited, a company incorporated in India.
The company will be engaged in wholesale supply of pharmaceutical products.

Note 2. Material accounting policies

This note provides a list of the significant accounting policies adopted in the preparation of these financial statements. The accounting policies adopted are consistent with those of the previous financial year.

(a) Basis of preparation

(i) Statement of compliance

These financial statements with limited information have been prepared solely for consideration in the consolidated financial statements of the Ultimate Parent Company. These financial statements have been prepared in accordance with the Ultimate Parent's accounting policies which are in agreement with the recognition and measurement principles laid down under the Companies (Indian Accounting Standards) Rules, 2015, as amended.

(ii) Historical cost convention

These financial statements have been prepared under historical cost convention on accrual basis, unless otherwise stated.

(b) Functional and presentation currency

Items included in the financial statements of the Company are measured using the currency of the primary economic environment in which the entity operates (i.e. the "functional currency"). The functional currency of the Company is Canadian Dollar ("CAD"). These financial statements are presented in CAD.

(c) Current versus non-current classification

The Company presents assets and liabilities in the Balance Sheet based on current/non-current classification.
An asset is treated as current when:

- It is expected to be realised or intended to be sold or consumed in normal operating cycle;
- It is held primarily for the purpose of trading;
- It is expected to be realised within twelve months after the reporting period; or
- It is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

The Company classifies all other assets as non-current.

A liability is current when:

- It is expected to be settled in normal operating cycle;
- It is held primarily for the purpose of trading;
- It is due to be settled within twelve months after the reporting period; or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.

The Company classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities respectively.

The operating cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents. The Company has identified twelve months as its operating cycle for the purpose of current-non-current classification of assets and liabilities.

Jubilant Pharmaceutical INC
Notes to the financial statements for the year ended 31 March 2026
(All amounts in CAD, unless otherwise stated)

Note 3: Cash and cash equivalents

	As at 31 March 2026
Balances with banks	
- in current accounts	29,965
Total cash and cash equivalents	**29,965**

Note 4: Equity share capital

	As at 31 March 2026
Paid up share capital	
30000 Common stock of no par value	30,000
	30,000

Movement in equity share capital	No. of shares	Amount
Additions during the year	30,000	30,000
As at 31 March 2026	30,000	30,000

Terms and rights attached to equity shares

The Company has only one class of Common stock referred to herein as equity shares. Each holder of common stock is entitled to one vote per common stock. In the event of liquidation of the Company, the stockholders shall be entitled to receive all of the remaining assets of the Company, after distribution of all preferential amounts, if any. Such amounts will be in proportion to the number of common stock of equity shares held by the stockholders.

Details of shareholders holding more than 5% shares in the Company:

	As at 31 March 2026	
	No. of shares	% holding
Jubilant Generics Limited - the holding company	30,000	100.00%
Common stock of no par value		

Jubilant Pharmaceutical INC

Notes to the financial statements for the year ended 31 March 2026

(All amounts in CAD, unless otherwise stated)

Note 5: Trade payables

	As at 31 March 2026
Current	
Dues to relates parties	40,187
Dues to others	811
Total trade payables	**40,998**

Note 6: Other expenses

	For the year ended 31 March 2026
Rates and taxes	40,187
Legal and professional fees	811
Bank charges	35
Total other expenses	**41,033**